Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$4.28 USD
-0.27 (-5.93%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $4.26 -0.02 (-0.47%) 5:56 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Acurx Pharmaceuticals, Inc.'s return on equity, or ROE, is -436.83% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that ACXP has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ACXP 4.28 -0.27(-5.93%)
Will ACXP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACXP
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
ACXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Other News for ACXP
ACXP forms Boomer Buy Setup on October 3
ACXP forms Non-ADX 1,2,3,4 Bearish on October 2
Bollinger Band Squeeze appears for ACXP after 7.23% move
Is ACXP signaling a buying opportunity? 20 Day Moving Average Support shows up after climbing 0.23%
ACXP: HC Wainwright & Co. Reiterates Buy Rating with $31 Price Target | ACXP Stock News